VolitionRX (NYSEAMERICAN:VNRX) released its earnings results on Monday. The medical research company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01, Morningstar.com reports.
Shares of VNRX stock opened at $3.92 on Wednesday. VolitionRX has a 12-month low of $1.67 and a 12-month high of $4.65.
In related news, Director Martin Charles Faulkes acquired 70,731 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were acquired at an average cost of $3.02 per share, with a total value of $213,607.62. The purchase was disclosed in a legal filing with the SEC, which is available at this link.
VolitionRX Company Profile
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.
See Also: Why do corrections happen?
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.